Verkazia 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
R/0021 
Renewal of the marketing authorisation. 
26/01/2023 
31/03/2023 
SmPC, Annex 
II, Labelling 
and PL 
IAIN/0022 
B.II.b.1.a - Replacement or addition of a 
13/02/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
ciclosporin (topical use) 
IB/0020 
B.II.c.2.d - Change in test procedure for an excipient 
04/10/2022 
n/a 
- Other changes to a test procedure (including 
replacement or addition) 
IA/0019/G 
This was an application for a group of variations. 
14/09/2022 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0017 
B.II.f.1.d - Stability of FP - Change in storage 
24/01/2022 
21/09/2022 
SmPC, 
conditions of the finished product or the 
diluted/reconstituted product 
Labelling and 
PL 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
ciclosporin (topical use) 
II/0013/G 
This was an application for a group of variations. 
28/10/2021 
21/09/2022 
SmPC, 
The SmPC has been updated as follows:  
B.II.e.1.b.2 - Change in immediate packaging of the 
PL 
new PFMD presentation; All sections of the SmPC are 
Labelling and 
The Product Information has been revised to include the 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Change in type/addition of a new 
identical to the current approved version for single-dose 
container - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.b.3.b - Change in the manufacturing process of 
the finished or intermediate product - Substantial 
changes to a manufacturing process that may have a 
significant impact on the quality, safety and efficacy 
of the medicinal product 
IB/0016 
B.II.c.1.z - Change in the specification parameters 
19/07/2021 
n/a 
and/or limits of an excipient - Other variation 
containers with the exception of sections: 
“4.2 Posology and method of administration”,: 
in paragraph “Method of administration” the text “For single 
use only. Each single-dose container is sufficient to treat 
both eyes. Any unused emulsion should be discarded 
immediately” has been deleted; 
the text “Patients should be informed of the correct 
handling of the multidose container. For instructions for 
use, see section 6.6” has been added; 
“6.3 Shelf life”:  
2 years. After first opening of the bottle: 4 weeks. Store 
below 25°C; 
“6.4 Special precautions for storage”: 
 Do not freeze. Store below 25°C. For storage conditions 
after first opening of the medicinal product, see section 
6.3; 
“6.5 Nature and contents of container”:  
Verkazia is supplied sterile in a white low density 
polyethylene bottle (9 mL fill in a 11 mL container) and 
white nozzle with tamper evident system.  Carton 
containing 1 bottle. 
“6.6 Special precautions for disposal”: instructions for use 
have been added for the new multidose container 
The Labelling and PL as well as Annex A have been updated 
accordingly. 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
ciclosporin (topical use) 
IG/1315 
B.II.b.5.a - Change to in-process tests or limits 
08/03/2021 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
ciclosporin (topical use) 
IB/0011 
B.III.1.z - Submission of a new/updated or deletion 
07/07/2020 
n/a 
of Ph. Eur. TSE Certificate of Suitability - Other 
variation 
IB/0009 
C.I.11.z - Introduction of, or change(s) to, the 
22/06/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
/201909 
ciclosporin (topical use) 
IG/1227/G 
This was an application for a group of variations. 
15/04/2020 
31/03/2021 
SmPC, Annex 
II and PL 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1163/G 
This was an application for a group of variations. 
21/11/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.c.3.z - Change in source of an excipient or 
reagent with TSE risk - Other variation 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
03/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201903 
ciclosporin (topical use) 
WS/1490 
This was an application for a variation following a 
29/05/2019 
04/07/2019 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10362
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
/201809 
ciclosporin (topical use) 
N/0004 
Minor change in labelling or package leaflet not 
25/03/2019 
04/07/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
B.II.e.z - Change in container closure system of the 
24/01/2019 
n/a 
Finished Product - Other variation 
Page 6/6 
 
 
 
 
 
 
 
 
 
